Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors
Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors
Recruiting · NCT06504368 · Registry updated 2025-11-06Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors | Solid Tumors, Adult | Recruiting | Phase 1 | 2025-11-06 | NCT06504368 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 3 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| NEXT Oncology | San Antonio | United States | 70 |
| NEXT Oncology | Irving | United States | 11 |